Vistagen Therapeutics, Inc. (VTGN): Shareholders' Equity
$35.52M
As of 2026-03-31
$24.48M
As of 2026-06-30
+43.3%
3-year compound annual growth
-17.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $35.52M | -49.5% | 2026-06-15, Balance as of period end |
| 2025-03-31 | $70.39M | -38.4% | 2026-06-15, Balance as of period end |
| 2024-03-31 | $114.29M | +846.1% | 2025-06-17, Balance as of period end |
| 2023-03-31 | $12.08M | -81.3% | 2024-06-11, Balance as of period end |
| 2022-03-31 | $64.72M | -29.6% | 2023-06-28, Balance as of period end |
| 2021-03-31 | $91.98M | n/m | 2022-06-23, Balance as of period end |
| 2020-03-31 | -$5.73M | n/m | 2021-06-29, Balance as of period end |
| 2019-03-31 | $7.08M | +2.3% | 2020-06-29, Balance as of period end |
| 2018-03-31 | $6.92M | n/m | 2019-06-25, Balance as of period end |
| 2017-03-31 | $615.8K | n/m | 2018-06-26, Balance as of period end |
| 2016-03-31 | -$2.98M | n/m | 2017-06-29, Balance as of period end |
| 2015-03-31 | -$20.54M | n/m | 2016-06-24, Balance as of period end |
| 2014-03-31 | -$12.80M | n/m | 2015-06-29, Balance as of period end |
| 2013-03-31 | -$12.56M | n/m | 2014-06-25, Balance as of period end |
| 2012-03-31 | -$5.71M | n/m | 2014-06-25, Balance as of period end |
| 2011-03-31 | -$32.88M | n/m | 2014-06-25, Balance as of period end |
| 2010-03-31 | -$26.34M | n/m | 2013-07-18, Balance as of period end |
| 2009-03-31 | -$26.68M | n/m | 2013-07-18, Balance as of period end |
| 2008-03-31 | -$22.17M | n/m | 2013-07-18, Balance as of period end |
| 2007-03-31 | -$17.45M | n/m | 2013-07-18, Balance as of period end |
| 2006-03-31 | -$16.50M | n/m | 2013-07-18, Balance as of period end |
| 2005-03-31 | -$14.74M | n/m | 2013-07-18, Balance as of period end |
| 2004-03-31 | -$13.69M | n/m | 2013-07-18, Balance as of period end |
| 2003-03-31 | -$4.95M | n/m | 2013-07-18, Balance as of period end |
| 2002-03-31 | -$4.58M | n/m | 2013-07-18, Balance as of period end |
| 2001-03-31 | -$2.51M | n/m | 2013-07-18, Balance as of period end |
| 2000-03-31 | -$844.1K | n/m | 2013-07-18, Balance as of period end |
| 1999-03-31 | -$225.5K | n/a | 2013-07-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $35.52M | -49.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $6.33M | -13.5% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $5.67M | -74.1% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$30.15M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $24.60M | +29.5% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$60.28M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.83M | -34.5% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $29.71M | +92.4% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | -$2.09M | n/m |
Compare VTGN, IGC, LGVN, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗